Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors

Cardiovascular disease (CVD) is the primary cause of death worldwide 1. The main risk factors for developing CVD are hyperlipidemia, high blood pressure, cigarette smoking and diabetes mellitus (DM) 2. The ESC guidelines have set distinct goals to prevent disease progression, following large clinical trials 3-5. The FOURIER study investigated the clinical benefit of LDL-C reduction in patients with atherosclerotic cardiovascular disease (ASCVD) and showed a 20% reduction of major adverse cardiovascular events (MACE) through an 59% LDL-C reduction 6.
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Tags: Original Research Source Type: research